40.3% Overall Response Rate (ORR) with Median Duration of Response of 5.8 Months and 19.3% Complete Response (CR) Rate with Median Duration of Response of 8.8 Months in Patients With a CR

Overall Safety Profile was Consistent with Previously Reported Data

Simultaneous Online Publications of Clinical and Translational Data Presented in Journal Blood

CHICAGO-Thursday, June 8th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral IDHIFA® (enasidenib) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-2 (IDH2) mutation. IDHIFA is an investigational first-in-class, oral, targeted inhibitor of the mutant IDH2 enzyme, which demonstrated an overall response rate of 40.3 percent, including a compl ... Read more »

JOHANNESBURG & CAPE TOWN, South Africa-Thursday, June 8th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Rand Merchant Investment Holdings (JSE:RMI) through AlphaCode, RMI’s innovation hub for fintech entrepreneurs and Nedbank Private Equity (“NPE”) through its private equity investment vehicle, BoE Private Equity Investments, have each acquired minority shareholdings in Entersekt in a multi-million dollar transaction. Entersekt is a Stellenbosch-based innovator that has developed world-class push-based authentication and app security technology.

The capital injection will be used to fund international expansion and research and development. All regulatory approvals have been obtained, including the Competition Commission of South Africa.

Entersekt targets global enterprises which require user-friendly and solid authentication and security products for interactions with their customers. Entersekt’s patented security products already protec ... Read more »

 The Nippon Foundation and UN DOALOS Join Hands to Achieve SDGs

TOKYO -Thursday, June 8th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- On June 7 (New York time), at an official function of the United Nations Ocean Conference, The Nippon Foundation announced the launch of new human resource capacity-building projects on ocean governance with the United Nations Division for Ocean Affairs and the Law of the Sea (UN DOALOS).

The high-level ocean conference is being held June 5-9, 2017, to support the implementation of Sustainable Development Goal 14, one of 17 goals of the 2030 Agenda for Sustainable Development adopted last September. The conference is also slated to adopt a “Call for Action,” consisting of targets and actions for the implementation of SDG 14.

“Call for Action” stresses the importance of support for developing nations and island nations, as well as support for women. The NF-UNDOALOS Capacity-Building Projects are p ... Read more »

Ras Al Khaimah, United Arab Emirates-Thursday, June 8th 2017 [ ME NewsWire ]

The Emirati pharmaceutical company Julphar Gulf Pharmaceutical Industries, one of the key players in the region, has launched a new drug – Dandasha – in the UAE market to treat erectile dysfunction (ED) in adult men.

Marketed in tablets form, Dandasha (Tadalafil 20 mg) is an inhibitor of phosphodiesterase type 5 (PDE5), which mediates relaxation of vascular smooth muscle in particular areas of the body, facilitating and maintaining erection for up to 36 hours.

Commenting on the launch of Dandasha, Julphar’s Marketing Director Dr Hosam Badr said: “Julphar has been active in many major therapeutic segments. ED is the 8th biggest segment in the UAE pharmaceutical market, with a market size estimated at AED 165 million and a common problem affecting 52% of men worldwide. We have been considering entering this segment for a while and with the launch ... Read more »